Immunic Q1 net loss $25.3M; positive phase 1b IMU-856 celiac data; cash $97.1M

IMMUNIC, INC.

2023-Q1 EPS reported -$0.58

Q1 net loss $25.3M ($0.58/sh) vs $20.8M ($0.74/sh); R&D expenses $23.0M up from $17.4M YoY.
Cash, equivalents and investments $97.1M as of Mar 31, 2023; expected to fund operations into Q4 2024.
Positive phase 1b IMU-856 celiac data: proof-of-concept with improvements in histology, symptoms, biomarkers, nutrient absorption.
Interim results from phase 2 CALLIPER trial of vidofludimus calcium in progressive MS expected H2 2023.
Richard Rudick, M.D. added to board Apr 26, 2023; Vincent Ossipow, Ph.D. to step down June 28, 2023.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

IMMUNIC, INC. reported financial results for first quarter ended March 31, 2023.

Period: first quarter ended March 31, 2023
Result: reported results

Exact text from the filing

On May 11, 2023, Immunic, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2023 and providing a corporate update (the “Press Release”).

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

IMMUNIC, INC. filing history →

Source: SEC EDGAR

accession 0001193805-23-000700

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.